The Mexico Insulin Delivery Device Market was valued at $66.6 Million in 2025 and projected to reach to $88.2 Million by 2030, representing a compound annual growth rate of 5.8%. Mexico's insulin delivery device market is positioned for moderate but consistent growth through 2030, driven by escalating diabetes incidence and expanding healthcare budgets.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico's insulin delivery device market is valued at USD 66.6 million in 2025, with projected growth to USD 88.2 million by 2030, representing a steady CAGR of 5.8%.
Rising diabetes prevalence across Mexico's urban and rural populations is a primary catalyst for market expansion, creating sustained demand for insulin delivery solutions.
Increasing healthcare expenditure in Mexico is enabling greater accessibility to advanced insulin delivery technologies, supporting market penetration and adoption rates.
Growing adoption of advanced insulin delivery devices among Mexican patients reflects improving healthcare infrastructure and increased awareness of modern diabetes management solutions.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INSULIN PUMPS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.3% from 2025 to 2030 |
| Largest Segment | TYPE 2 DIABETES (Disease Type) |
| Market Size Base Year (Billions) | ~USD 35.37 (2025) |
| Revenue Forecast (Billions) | ~USD 52.7 (2030) |
| Segments Covered | Type, Disease Type, End User |
3 segment dimensions are covered across the global market.
| Segment | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|
| HOME CARE SETTINGS | 314.4 | 337 | 362.1 | 390.2 | 421.6 | 443 | 7.1 |
| HOSPITALS & CLINICS | 147.4 | 156.8 | 167.1 | 178.6 | 191.4 | 199.4 | 6.2 |
| OTHER END USERS | 31 | 33.3 | 35.8 | 38.6 | 41.8 | 43.9 | 7.2 |
| TOTAL | 492.9 | 527.1 | 565.1 | 607.5 | 654.8 | 686.4 | 6.8 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Injectable and infusion-based therapies in long-term acute care hospitals,Oral therapies in inpatient rehabilitation facilities,Contract rehabilitation and ancillary sites using mixed delivery routes, |
| F5 NETWORKS | United States | Public Company | BIG-IP Systems and Packaged Software,NGINX (Plus, One Console, Ingress, WAF),Distributed Cloud Services (WAAP, Multi-cloud Networking, CDN, DNS), |
| DIALOG SEMICONDUCTOR PLC | United Kingdom | Private Company | Custom Mixed Signal (PMICs, battery management, display power, motor control),Advanced Mixed Signal (configurable ICs, AC/DC, LED and SSL drivers),Connectivity & Audio (BLE, Wi-Fi SoCs, audio CODECs), |
Kindred Healthcare Inc. is a United States-based private company founded in 1985 that operates as a major healthcare services provider. With 64,200 employees, the company delivers a range of healthcare services across multiple care settings.
F5 Networks is a publicly traded United States company founded in 1996 with 6,545 employees that specializes in application delivery networking and security solutions.
Dialog Semiconductor PLC is a United Kingdom-based private company founded in 1998 with 2,300 employees that develops semiconductor solutions.
Mexico's insulin delivery device market is valued at USD 66.6 million in 2025 and is expected to reach USD 88.2 million by 2030.
Mexico's insulin delivery device market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2030.
Growth in Mexico is driven by increasing diabetes prevalence, rising healthcare expenditure, expanding middle-class purchasing power, improved reimbursement frameworks, and government healthcare initiatives promoting insulin therapy adoption.
Mexico's market includes insulin pens, insulin pumps, and syringes, with pens representing the largest segment due to ease of use and affordability compared to pump systems.
Mexico represents a significant portion of the Latin American insulin delivery device market due to its large diabetic population, developed healthcare infrastructure, and streamlined regulatory pathways that facilitate faster product launches.
The study focused on estimating the current market size of the insulin delivery devices sector. Comprehensive secondary research was conducted to gather information about the industry. The next step involved validating these findings, assumptions, and estimates by consulting industry experts throughout the value chain through primary research. Various methods were used to calculate the total market size, including top-down and bottom-up approaches. Subsequently, market segmentation and data triangulation procedures were employed to determine the size of the segments and subsegments within the insulin delivery devices market.
The secondary research process involves utilizing a range of secondary sources, including directories and databases such as Bloomberg Business, Factiva, and D&B Hoovers. It also encompasses white papers, annual reports, investor presentations, SEC filings from companies, and publications from various government sources. Notable organizations referenced include the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the US Census Bureau, the World Health Organization (WHO), the International Trade Administration (ITA), the Global Burden of Disease Study, and the Centers for Medicare and Medicaid Services (CMS).
These resources were used to gather information for the global insulin delivery devices market study. They provided crucial insights into key players within the market, as well as market classification and segmentation based on industry trends. Additionally, important developments related to market and technology perspectives were identified. A database of key industry leaders was also compiled using the information obtained through secondary research.
In the primary research process, interviews were conducted with various sources from both the supply and demand sides to gather qualitative and quantitative information for this report. The supply-side primary sources included industry experts, such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from important companies and organizations in the insulin delivery devices market. On the demand side, the primary sources included personnel from home care settings, hospitals, clinics, and other end users. This primary research was carried out to validate market segmentation, identify key players in the market, and gather insights on essential industry trends and dynamics.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, CFOs, COOs, and VPs.
Note 2: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = < USD 1 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs (original equipment manufacturers) operating in the global insulin delivery devices market to determine the global market value. All significant product manufacturers were identified at both the global and country/regional levels. Revenue mapping for these key players was conducted for the relevant business segments and subsegments. Additionally, the global insulin delivery devices market was divided into various segments and subsegments based on specific criteria:
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

After arriving at the overall size of the global insulin delivery devices market through the above-mentioned methodology, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Insulin delivery devices are medical devices designed to administer insulin, a hormone used in the management of diabetes, into the body. These devices are primarily used by individuals with diabetes who require insulin therapy to regulate their blood sugar levels. Insulin pens, pumps, pen needles, and syringes are the most widely used delivery devices.
Full forecast, segment splits, and company analysis for all Insulin Delivery Device Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report